Abstracts tagged "Polymyalgia rheumatica and prognostic factors"

Abstract Number: 756 • 2019 ACR/ARP Annual Meeting
A Volar Pattern of 18F-Fluorodeoxyglucose Uptake at the Hand on Whole Body PET/CT Predicts Glucocorticoid-Responsive Disease in Polymyalgia Rheumatica
Claire Owen¹, Aurora Poon ¹, Sze Ting Lee ¹, Chris McMaster ¹, Jessica Leung ¹, David Liew ¹, Andrew Scott ¹ and Russell Buchanan ¹, ¹Austin Health, Heidelberg, Victoria, Australia
Background/Purpose: Almost half of all patients diagnosed with PMR require a protracted duration of glucocorticoid therapy due to relapsing disease.(1) On whole body PET/CT, PMR…
Abstract Number: 2107 • 2017 ACR/ARHP Annual Meeting
Therapeutic Response to Prednisone in Relation to Age in Polymyalgia Rheumatica: A Controlled Study
Aline Charpentier¹, Frank Verhoeven^2,3, Maxime Sondag¹, Xavier Guillot⁴, Clément Prati⁵ and Daniel Wendling⁶, ¹rheumatology, CHU de Besançon, Besancon, France, ²EA 4267 FDE, FHU INCREASE, Université de Bourgogne Franche-Comté, Besançon, France, ³Service de Rhumatologie, CHRU J Minjoz, Besançon, France, ⁴EA 4267 FDE, FHU INCREASE, Université de Bourgogne FrancheComté, Besançon, France, ⁵Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁶Service de Rhumatologie, CHU Jean Minjoz, Besancon, France
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disorder which usually affect patients over 65 years old. Different poor prognostic factors are involved in prednisone…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].